Armata Pharmaceuticals Reports Positive Phase 2a Results for AP-SA02 in Staph Aureus Bacteremia

Armata Pharmaceuticals announced positive Phase 2a results for its investigational phage therapy, AP-SA02, in treating Staphylococcus aureus bacteremia. The diSArm study showed that AP-SA02 combined with best available antibiotic therapy (BAT) achieved higher and earlier cure rates compared to BAT alone, with a 100% response rate and no relapse. AP-SA02 was well-tolerated and effective against both methicillin-resistant and methicillin-sensitive S. aureus. The company will discuss these findings in a webinar on November 25, 2025.

Armata Pharmaceuticals: Strategic Advancements and Clinical Progress Drive Buy Rating

Joseph Pantginis from H.C. Wainwright reiterated a Buy rating for Armata Pharmaceuticals with a $9.00 price target. The rating is based on the company's operational readiness, strategic focus on clinical trials, and the commissioning of a cGMP phage manufacturing facility. Recent positive data from the diSArm study and active engagement with the FDA for a Phase 3 trial design further support this rating. Despite financial challenges, the company's strategy to secure funding through equity raises and grants is promising.

Armata Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

Armata Pharmaceuticals | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 1.159 M

Armata Pharmaceuticals reports third quarter loss from operations of $7.8 million

Armata Pharmaceuticals Inc. reported a third-quarter loss from operations of $7.8 million for the period ending September 30, 2025, an improvement from a $9.8 million loss in the same quarter of 2024. The company had $14.8 million in unrestricted cash as of September 30, 2025, up from $9.3 million at the end of 2024. Additionally, positive results from the Phase 2a “diSArm” study of its lead therapeutic phage candidate, AP-SA02, were presented at IDWeek 2025.